In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive Summary
St. Jude: Pacesetter subsidiary gains FDA approval of a PMA supplement for its Passive Plus TiN pacemaker lead. The TiN lead features an electrode tip coated with titanium nitride, which St. Jude says "has been shown to increase the microscopic surface area of the electrode tip and to reduce polarization." St. Jude also announces receipt of an investigational device exemption for its Passive Plus DX lead and export approval to sell its AV Plus lead in Sweden. The Passive Plus DX has a "steroid-eluding electrode" in addition to titanium nitride coating. The steroid-eluding AV Plus lead, in clinicals in the U.S. and Europe, is indicated exclusively for use with Pacesetter's AddVent VDDR pulse generator; the product "enables AddVent to sense the atrium and ventricle and to pace the ventricle appropriately using a single lead," St. Jude says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.